 Zacks Investment Research upgraded shares of resTORbio NASDAQ:TORC from a hold rating to a buy rating in a report released on Wednesday morning, Zacks.com reports. They currently have 1.25 price objective on the stock. According to Zacks, resTORbio, Inc. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of therapeutics for the ... 